Evidence map›Paper›PMID 28696418›Full record

ArticleThe pharmacogenomics journal2018

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.

N D Loft, L Skov, L Iversen, R Gniadecki, T N Dam, I Brandslund, H J Hoffmann, M R Andersen, R B Dessau, A C Bergmann and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pharmacogenomics of TNF inhibitors.Frontiers in immunology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Observational
  14. Review
  15. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

N D LoftDepartment of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
L SkovDepartment of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
L IversenDepartment of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
R GniadeckiDepartment of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
T N DamSkin Clinic, Nykoebing Falster, Denmark.
I BrandslundDepartment of Clinical Immunology and Biochemistry, Lillebaelt Hospital, Vejle, Denmark.
H J HoffmannInstitute of Clinical Medicine, Aarhus University, and Department of Respiratory Diseases and Allergy B, Aarhus University Hospital, Aarhus, Denmark.
M R AndersenDepartment of Clinical Biochemistry, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
R B DessauDepartment of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark.
A C BergmannFocused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Soenderjylland, Laboratory Center, Hospital of Southern Jutland, Aabenraa, Denmark.
N M AndersenFocused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Soenderjylland, Laboratory Center, Hospital of Southern Jutland, Aabenraa, Denmark.
P S AndersenDepartment of Microbiology and Infection Control, Serum Institute, Copenhagen, Denmark.
S BankFocused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Soenderjylland, Laboratory Center, Hospital of Southern Jutland, Aabenraa, Denmark.
U VogelNational Research Centre for the Working Environment, Copenhagen, Denmark.
V AndersenFocused Research Unit for Molecular Diagnostic and Clinical Research, IRS-Center Soenderjylland, Laboratory Center, Hospital of Southern Jutland, Aabenraa, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biological agents including anti-tumor necrosis factor (anti-TNF; adalimumab, infliximab, etanercept) and anti-interleukin-12/13 (IL12/23; ustekinumab) are essential for treatment of patients with severe psoriasis. However, a significant proportion of the patients do not respond to a specific treatment. Pharmacogenetics might be a way to predict treatment response. Using a candidate gene approach, 62 mainly functional single-nucleotide polymorphisms (SNPs) in 44 different genes were evaluated in 478 Danish patients with psoriasis undergoing 376 series of anti-TNF treatment and 230 series of ustekinumab treatment. Associations between genetic variants and treatment outcomes (drug survival and Psoriasis Area Severity Index reduction) were assessed using logistic regression analyses (crude and adjusted for gender, age, psoriatic arthritis and previous treatment). After correction for multiple testing controlling the false discovery rate, six SNPs (IL1B (rs1143623, rs1143627), LY96 (rs11465996), TLR2 (rs11938228, rs4696480) and TLR9 (rs352139)) were associated with response to anti-TNF treatment and 4 SNPs (IL1B (rs1143623, rs1143627), TIRAP (rs8177374) and TLR5 (rs5744174)) were associated with response to ustekinumab treatment (q<0.20). The results suggest that genetic variants related to increased IL-1β levels may be unfavorable when treating psoriasis with either anti-TNF or ustekinumab, whereas genetic variants related to high interferon-γ levels may be favorable when treating psoriasis with ustekinumab.

Indexed as

AdalimumabAdultDenmarkEtanerceptFemaleHumansInfliximabInterleukin-1betaLymphocyte Antigen 96MaleMembrane GlycoproteinsMiddle AgedPharmacogeneticsPolymorphism, Single NucleotidePsoriasisReceptors, Interleukin-1AdalimumabEtanerceptIL1B protein, humanInfliximabInterleukin-1betaLY96 protein, humanLymphocyte Antigen 96Membrane GlycoproteinsReceptors, Interleukin-1TIRAP protein, humanTLR2 protein, humanTLR9 protein, humanToll-Like Receptor 2Toll-Like Receptor 9Tumor Necrosis Factor-alphaUstekinumab

Identifiers

PMID28696418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.